Patent intelligence · US
US 2016159901
DIAGNOSIS AND THERAPY OF CANCER INVOLVING CANCER STEM CELLS
DIAGNOSIS AND THERAPY OF CANCER INVOLVING CANCER STEM CELLS
Patent details — US 2016159901
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 9, 2016
- Expiration
- Jun 4, 2036
- Applicant
- GANYMED PHARMACEUTICALS AG [DE]
- CPC classes
- A61K 31/ 337 A I, A61K 31/ 5365 A I, A61K 31/ 7048 A I, A61K 31/ 7064 A I
Quick answer
US 2016159901 (DIAGNOSIS AND THERAPY OF CANCER INVOLVING CANCER STEM CELLS) is held by GANYMED PHARMACEUTICALS AG [DE]. Status: granted. Granted Jun 9, 2016. Expires Jun 4, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- GANYMED PHARMACEUTICALS AG [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 337 A I, A61K 31/ 5365 A I, A61K 31/ 7048 A I, A61K 31/ 7064 A I, A61K 33/ 243 A I, A61K 39/ 395 A I
More from GANYMED PHARMACEUTICALS AG [DE]
Related pharmaceutical patents in our USPTO index.
-
AU 2022206771
Drug conjugates comprising antibodies against Claudin 18.2
granted -
EP 3791896
KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS
granted -
LT 3254695
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted -
EP 3708579
CLAUDIN-6-SPEZIFISCHE IMMUNREZPTOREN UND T-ZELL-EPITOPE
granted -
HR P20200591
ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)
granted -
US 2020199221
ANTIBODIES USEFUL IN CANCER DIAGNOSIS
granted -
WO 2020095183
COMBINAISON POUR LE TRAITEMENT DU CANCER
granted -
US 2019076525
THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted
Frequently asked questions
What is US patent 2016159901?
US 2016159901 (DIAGNOSIS AND THERAPY OF CANCER INVOLVING CANCER STEM CELLS) is held by GANYMED PHARMACEUTICALS AG [DE]. Status: granted. Granted Jun 9, 2016. Expires Jun 4, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2016159901?
GANYMED PHARMACEUTICALS AG [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2016159901 expire?
Our index shows an expiration date of Jun 4, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.